22 February 2026

Navigating Systemic Mastocytosis: A Patient’s Journey to Diagnosis and Care

Patient Advocate Suki Tipp’s Journey Through Misdiagnosis to Effective Treatment

In a compelling episode of the Derm Dispatch series, patient advocate Suki Tipp shares her harrowing experience transitioning from misdiagnosed skin issues and disjointed specialty care to facing life-threatening anaphylaxis and ultimately achieving disease control through targeted therapy.

WATCH TIME: 31 minutes | Captions are auto-generated and may contain errors.

Exploring the Impact of Delayed Diagnosis

During her conversation with host Renata Block, DMSc, MMS, PA-C, Tipp delves into the clinical, emotional, and financial burdens associated with a delayed diagnosis of indolent systemic mastocytosis. She underscores the vital role that dermatology professionals can play in recognizing this rare condition sooner, which could transform outcomes for patients.

Initial Symptoms and Misinterpretations

Tipp’s journey began in 2015 with the onset of intensely itchy lesions on her legs, which she initially attributed to shaving or environmental factors. These red, hive-like spots eventually morphed into persistent brown macules. Unfortunately, these changes were misdiagnosed as folliculitis accompanied by post-inflammatory hyperpigmentation.

At the time, Tipp did not correlate her skin manifestations with systemic symptoms such as flushing, severe gastrointestinal distress, diarrhea, headaches, and mood fluctuations. She explained that the episodic and seemingly unrelated nature of her symptoms posed significant challenges for both her and the healthcare providers she consulted.

The Turning Point: Anaphylaxis

A life-altering event occurred when Tipp experienced a severe anaphylactic reaction triggered by a wasp sting, necessitating critical care. Following this incident, she was referred to an allergist who suspected systemic mastocytosis. However, the fragmentation of specialty care continued, as a requested skin punch biopsy was postponed after a dermatological evaluation deemed her lesions inconsistent with mastocytosis.

As her condition deteriorated, Tipp found herself requiring an alarming 99 epinephrine auto-injectors within a single year due to recurrent anaphylactic episodes triggered by various allergens, including foods, environmental factors, and even airborne irritants. This drastic escalation in her health issues forced her to leave her job and restrict her diet to only a few “safe” food options and select bottled water.

The Challenge of Interdisciplinary Care

Throughout her diagnostic journey, Tipp experienced a lack of collaboration among different specialties. She highlighted that no single clinician managed to unify her dermatological, gastrointestinal, allergic, and neuropsychiatric symptoms into a cohesive diagnosis.

“When you go to a GI doctor for the stomach pain or the diarrhea that you’re having, they don’t ask you about your skin,” Tipp lamented.

The Psychological and Financial Strain

The psychological toll of living with a rare disease like mastocytosis is significant. Tipp discussed the stigma surrounding mental health issues that can arise during mast cell flares, as well as the anxiety of being dismissed by clinicians who may not understand systemic mastocytosis.

Financial toxicity only intensified her struggles. The cost of high-dose antihistamines, mast cell stabilizers, and other supportive therapies often led her to ration her medications. Tipp urged healthcare providers to openly discuss medication affordability and foster transparency regarding adherence challenges.

A Path to Recovery: Targeted Therapy

Ultimately, Tipp’s breakthrough came when she enrolled in a clinical trial for avapritinib (Ayvakit; Blueprint Medicines) at the University of Alabama at Birmingham. This followed an oncologist’s recognition of the molecular basis for KIT inhibition. Remarkably, within six to eight months, she noted significant improvements in both her cutaneous and systemic symptoms, including a gradual reduction in hyperpigmented lesions and a marked decrease in anaphylactic episodes.

Advocacy and Awareness

Now a passionate advocate, Tipp encourages dermatology clinicians to consider systemic mastocytosis in patients presenting with recurrent urticaria, flushing, unexplained brown macules, and systemic symptoms. She stresses the importance of transparency among clinicians—acknowledging knowledge gaps while committing to further research—and emphasizes the need for a comprehensive, multidisciplinary approach rather than merely managing isolated symptoms.

“I would much rather have a doctor… say, ‘I don’t know, but I promise I’m going to learn about it,’ than to pretend,” Tipp expressed.